AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27129908 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-inferior tibiofibular ligament (AITFL) anatomical repair with augmentation
Number of subjects: 53
Study 27129908 — intervention group
Group type: COMPARATOR
Intervention: Trans-syndesmosis screw fixation
Number of subjects: 53
Study 24419415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 225
Study 24419415 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel
Number of subjects: 225
Study 22812499 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE-guided ablation
Number of subjects: 102
Study 22812499 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-only group
Number of subjects: 102
Study 19275982 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM program in a school-based setting (1000 students, completed over five weeks)
Number of subjects: 8207
Study 19275982 — intervention group
Group type: COMPARATOR
Intervention: MoodGYM program in an open access community setting (7207 adolescents)
Number of subjects: 8207
Study 17967111 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication-centered life skills program implemented over 15 to 20 weeks
Number of subjects: 1581
Study 17967111 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1581
Study 15165599 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial glide taping
Number of subjects: 30
Study 15165599 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo taping (no glide)
Number of subjects: 30
Study 15165599 — intervention group
Group type: COMPARATOR
Intervention: No tape (control)
Number of subjects: 30
Study 11474002 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a
Number of subjects: 177
Study 11474002 — intervention group
Group type: COMPARATOR
Intervention: standard interferon alpha-2a
Number of subjects: 177
Study 11474002 — intervention group
Group type: EXPERIMENTAL
Intervention: virologic nonresponders (both treatments)
Number of subjects: 177
Study 9710889 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor-α monoclonal antibody therapy
Number of subjects: 0
Study 7822588 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Association Task (CAT)
Number of subjects: 72
Study 7822588 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Ordered Pointing (SOP) Task
Number of subjects: 72
Study 7822588 — intervention group
Group type: COMPARATOR
Intervention: High provocation condition (electric shocks received)
Number of subjects: 72
Study 7822588 — intervention group
Group type: COMPARATOR
Intervention: Low provocation condition (electric shocks received)
Number of subjects: 72
Study 2839433 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up patient education program
Number of subjects: 51
Study 2839433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone follow-up education)
Number of subjects: 51
Study 31251368 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to gun violence in video games
Number of subjects: 0
Study 31251368 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28063515 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation (3 g/d of fish oil containing 37% eicosapentaenoic acid and 23% docosahexaenoic acid)
Number of subjects: 80
Study 28063515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g/d of sunflower oil containing 65% linoleic acid)
Number of subjects: 80
Study 25933399 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens wearers
Number of subjects: 70
Study 25933399 — intervention group
Group type: COMPARATOR
Intervention: Nonwearers
Number of subjects: 70
Study 25933399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 23967126 — intervention group
Group type: EXPERIMENTAL
Intervention: trivalent inactivated influenza vaccine
Number of subjects: 340
Study 23967126 — intervention group
Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 340
Study 21324143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous fixation
Number of subjects: 104
Study 21324143 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 104
Study 19118379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg once daily
Number of subjects: 0
Study 19118379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg twice daily
Number of subjects: 0
Study 17393330 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum + fructo-oligosaccharides (FOS)
Number of subjects: 60
Study 17393330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16099893 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of training with acute exercise bouts
Number of subjects: 0
Study 16099893 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 0
Study 16099893 — intervention group
Group type: COMPARATOR
Intervention: Low-glycogen acute exercise trial
Number of subjects: 0
Study 16099893 — intervention group
Group type: COMPARATOR
Intervention: Normal-glycogen acute exercise trial
Number of subjects: 0
Study 12362670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound at 0.5 W/cm2
Number of subjects: 0
Study 12362670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound at 1 W/cm2
Number of subjects: 0
Study 12362670 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods (Control)
Number of subjects: 0
Study 9988796 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 g/day)
Number of subjects: 28
Study 9988796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7477617 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV-positive patients treated on separate machines
Number of subjects: 289
Study 7477617 — intervention group
Group type: COMPARATOR
Intervention: Anti-HCV-positive and anti-HCV-negative patients shared the same machines
Number of subjects: 289
Study 2248817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine at 19 degrees C
Number of subjects: 45
Study 2248817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine at 37 degrees C (sitting position)
Number of subjects: 45
Study 2248817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine at 37 degrees C (lateral horizontal position)
Number of subjects: 45
Study 6168363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin-radiotherapy protocol (15 mg bleomycin I.V. on alternate days followed by radiation)
Number of subjects: 25
Study 6168363 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 25
Study 6168363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin-radiotherapy protocol
Number of subjects: 25
Study 31758887 — intervention group
Group type: EXPERIMENTAL
Intervention: INSURE technique
Number of subjects: 14
Study 31758887 — intervention group
Group type: EXPERIMENTAL
Intervention: MIST technique
Number of subjects: 14
Study 27501352 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab for 6 months followed by 6 months of observation
Number of subjects: 15
Study 27501352 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 15
Study 27501352 — intervention group
Group type: EXPERIMENTAL
Intervention: C1q status modeling
Number of subjects: 15
Study 27501352 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 15
Study 26625549 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation for 12 weeks
Number of subjects: 82
Study 26625549 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 82
Study 23490458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 21904964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting a blood glucose level between 4.4 and 6.1 mmol/l (n = 125)
Number of subjects: 248
Study 21904964 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy targeting a blood glucose level less than 11.0 mmol/l (n = 123)
Number of subjects: 248
Study 21904964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 248
Study 19556554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalists
Number of subjects: 0
Study 19556554 — intervention group
Group type: COMPARATOR
Intervention: Teaching teams
Number of subjects: 0
Study 17436172 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Leg
Number of subjects: 0
Study 14712285 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antithymocyte globulin 15 mg/kg/day for 5 days
Number of subjects: 35
Study 14712285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin 3.75 mg/kg/day for 5 days
Number of subjects: 35
Study 11704367 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Angioplasty and Stenting (CAS)
Number of subjects: 104
Study 11704367 — intervention group
Group type: COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 104
Study 9446334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (chemotherapy and radiotherapy) for advanced rectal cancer (T3N1M0 or T4N2M1) and localized large bowel cancer (G2 and G3 grading)
Number of subjects: 800
Study 9446334 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 800
Study 8426205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation (group A, 31 patients)
Number of subjects: 100
Study 8426205 — intervention group
Group type: COMPARATOR
Intervention: No cranial irradiation (group B, 25 patients)
Number of subjects: 100
Study 3445125 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50 Gy in 20 fractions to the kidney bed, ipsi‐ and contralateral lymph nodes)
Number of subjects: 65
Study 3445125 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 65
Study 3445125 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 65
Study 3445125 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II tumours
Number of subjects: 65
Study 3445125 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy vs observation
Number of subjects: 65
Study 31930414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical button
Number of subjects: 42
Study 31930414 — intervention group
Group type: COMPARATOR
Intervention: Interference screw
Number of subjects: 42
Study 31930414 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-loaded 2.9-mm polyetheretherketone anchor (DL-2.9)
Number of subjects: 42
Study 31930414 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-loaded 1.9-mm all-suture anchor (DL-1.9)
Number of subjects: 42
Study 31930414 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-loaded 1.7-mm all-suture anchor (SL-1.7)
Number of subjects: 42
Study 31930414 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue tenodesis
Number of subjects: 42
Study 29605500 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment (N=98)
Number of subjects: 174
Study 29605500 — intervention group
Group type: COMPARATOR
Intervention: High SPN
Number of subjects: 174
Study 29605500 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from low to high SPN
Number of subjects: 174
Study 29605500 — intervention group
Group type: COMPARATOR
Intervention: High MPN
Number of subjects: 174
Study 29605500 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from low to high MPN
Number of subjects: 174
Study 26956698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) 400 mg and Velpatasvir (VEL) 100 mg for 12 weeks
Number of subjects: 740
Study 26956698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study 25694008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shockwave therapy (LI-ESWT)
Number of subjects: 135
Study 25694008 — intervention group
Group type: COMPARATOR
Intervention: Placebo/sham therapy
Number of subjects: 135
Study 23206923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline total cholesterol levels
Number of subjects: 3957
Study 23206923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline triglyceride levels
Number of subjects: 3957
Study 21672334 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg alendronate once every 2 weeks plus 0.5 μg alfacalcidol daily
Number of subjects: 180
Study 21672334 — intervention group
Group type: COMPARATOR
Intervention: alfacalcidol 0.5 μg daily alone
Number of subjects: 180
Study 19364334 — intervention group
Group type: EXPERIMENTAL
Intervention: Venom Immunotherapy (VIT)
Number of subjects: 55
Study 19364334 — intervention group
Group type: COMPARATOR
Intervention: EpiPen
Number of subjects: 55
Study 16394086 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% glucose (200 mg/m2.min)
Number of subjects: 16
Study 16394086 — intervention group
Group type: COMPARATOR
Intervention: saline (50 ml/h)
Number of subjects: 16
Study 15333400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 15 mg
Number of subjects: 90
Study 15333400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mg
Number of subjects: 90
Study 15333400 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 10 mg
Number of subjects: 90
Study 11096165 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg)
Number of subjects: 632
Study 11096165 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 632
Study 9116923 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 13
Study 9116923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8380687 — intervention group
Group type: COMPARATOR
Intervention: 254‐S
Number of subjects: 0
Study 8380687 — intervention group
Group type: COMPARATOR
Intervention: DWA2114R
Number of subjects: 0
Study 8380687 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatinum
Number of subjects: 0
Study 2901609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 150
Study 2901609 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 150
Study 31786652 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model based on pre-treatment ADC image-derived radiomics features
Number of subjects: 89
Study 31786652 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model based on the top 10 most relevant features
Number of subjects: 89
Study 29652081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 227
Study 29652081 — intervention group
Group type: COMPARATOR
Intervention: High ligation and surgical stripping (HL/S)
Number of subjects: 227
Study 29652081 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 227
Study 28760799 — intervention group
Group type: EXPERIMENTAL
Intervention: High FIO2 group (80% oxygen; FIO2 of 0.80)
Number of subjects: 756
Study 28760799 — intervention group
Group type: COMPARATOR
Intervention: Conventional FIO2 group (30% oxygen; FIO2 of 0.30)
Number of subjects: 756
Study 26277172 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum concentrations of NO in women with premature delivery
Number of subjects: 73
Study 26277172 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum concentrations of NO in patients with spontaneous uterine activity without PROM
Number of subjects: 73
Study 26277172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin levels
Number of subjects: 73
Study 26277172 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 73
Study 22612371 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + HA/β‐TCP
Number of subjects: 34
Study 22612371 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 34
Study 22612371 — intervention group
Group type: COMPARATOR
Intervention: EMD
Number of subjects: 34
Study 21364992 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information and participant's prior expectations regarding basic intentions
Number of subjects: 0
Study 21364992 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information and participant's prior expectations regarding superordinate intentions
Number of subjects: 0
Study 21364992 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information and participant's prior expectations regarding social intentions
Number of subjects: 0
Study 18676227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid (1 g)
Number of subjects: 30
Study 18676227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 g)
Number of subjects: 30
Study 16822633 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin formulation 1
Number of subjects: 24
Study 16822633 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin formulation 2
Number of subjects: 24
Study 12838698 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Oratest
Number of subjects: 60
Study 12838698 — intervention group
Group type: COMPARATOR
Intervention: Rinse application of Oratest
Number of subjects: 60
Study 10393397 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus enalaprilat (0.004 mg/kg)
Number of subjects: 20
Study 10393397 — intervention group
Group type: COMPARATOR
Intervention: Continuous enalaprilat infusion (0.004 mg/kg)
Number of subjects: 20
Study 8913991 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT plus AA/Alanon (AA/ABMT)
Number of subjects: 90
Study 8913991 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT plus relapse prevention (RP/ABMT)
Number of subjects: 90
Study 8913991 — intervention group
Group type: COMPARATOR
Intervention: ABMT
Number of subjects: 90
Study 8913991 — intervention group
Group type: EXPERIMENTAL
Intervention: AA/ABMT
Number of subjects: 90
Study 8913991 — intervention group
Group type: EXPERIMENTAL
Intervention: AA attendance patterns
Number of subjects: 90
Study 1676233 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms/kg edrophonium (EDRO500)
Number of subjects: 18
Study 1676233 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 micrograms/kg edrophonium (EDRO1000)
Number of subjects: 18
Study 1676233 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg neostigmine (NEO40)
Number of subjects: 18
Study 6214925 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 65
Study 6214925 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 65
Study 31116848 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP
Number of subjects: 128
Study 31116848 — intervention group
Group type: COMPARATOR
Intervention: Conservative Medical Therapy (CMT)
Number of subjects: 128
Study 31116848 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-CPAP
Number of subjects: 128
Study 28726767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat taste sensitivity (FTT) assessed by 3-alternate forced choice methodology
Number of subjects: 69
Study 28726767 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 69
Study 26459006 — intervention group
Group type: EXPERIMENTAL
Intervention: Shinbaro pharmacopuncture
Number of subjects: 60
Study 26459006 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 26459006 — intervention group
Group type: COMPARATOR
Intervention: Usual care (conventional medication and physical therapy)
Number of subjects: 60
Study 23417014 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline motivation and longitudinal changes in motivation during a 26-week vocational rehabilitation program
Number of subjects: 123
Study 23417014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition at baseline
Number of subjects: 123
Study 23417014 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 123
Study 21859266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (Esbriet(®))
Number of subjects: 0
Study 21859266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18719941 — intervention group
Group type: EXPERIMENTAL
Intervention: OXXEL (oxaliplatin 100 mg/m² i.v. on day 1, capecitabine 1,000 mg/m² orally twice daily from day 1 to day 11)
Number of subjects: 322
Study 18719941 — intervention group
Group type: COMPARATOR
Intervention: OXAFAFU (oxaliplatin 85 mg/m² i.v. on day 1; 6S‐leucovorin 250 mg/m² i.v. and fluorouracil 850 mg/m² i.v. on day 2)
Number of subjects: 322
Study 18719941 — intervention group
Group type: EXPERIMENTAL
Intervention: OXXEL
Number of subjects: 322
Study 18719941 — intervention group
Group type: COMPARATOR
Intervention: OXAFAFU
Number of subjects: 322
Study 17138634 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exhaustive exercise
Number of subjects: 12
Study 17138634 — intervention group
Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 12
Study 15488877 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 32
Study 15488877 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg combined with Ramipril 10 mg
Number of subjects: 32
Study 11469424 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 97
Study 11469424 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 97
Study 9630850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve preservation (Group I)
Number of subjects: 128
Study 9630850 — intervention group
Group type: COMPARATOR
Intervention: Nerve section (Group II)
Number of subjects: 128
Study 8163828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(7) cfu
Number of subjects: 30
Study 8163828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(8) cfu
Number of subjects: 30
Study 8163828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(9) cfu
Number of subjects: 30
Study 8163828 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 30
Study 3422243 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine solution
Number of subjects: 24
Study 3422243 — intervention group
Group type: COMPARATOR
Intervention: 0.001 molar solution of quinine hydrochloride (placebo rinse)
Number of subjects: 24